Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Sigilon Therapeutics Inc.

    NASDAQ: SGTX · Real-Time Price · USD
    22.47
    -0.59 (-2.56%)
    At close: Aug 10, 2023, 8:00 PM

    Sigilon Therapeutics Statistics

    Share Statistics

    Sigilon Therapeutics has 2.5M shares outstanding. The number of shares has increased by 2.94% in one year.

    Shares Outstanding

    n/a
    		 2.5M

    Shares Change (YoY)

    n/a
    		 2.94%

    Shares Change (QoQ)

    n/a
    		 0.18%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 27

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 8.23K, so 0.33% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 8.23K

    Short % of Shares Out

    n/a
    		 0.33%

    Short % of Float

    n/a
    		 0.48%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -3.39 and the forward PE ratio is null. Sigilon Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -3.39

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 11.39

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 3.77

    P/FCF Ratio

    n/a
    		 -2.83

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Sigilon Therapeutics has an Enterprise Value (EV) of 133.44M.

    EV / Sales

    n/a
    		 10.31

    EV / EBITDA

    n/a
    		 -3.23

    EV / EBIT

    n/a
    		 -2.59

    EV / FCF

    n/a
    		 -2.57

    Financial Position

    The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.72.

    Current Ratio

    n/a
    		 2.4

    Quick Ratio

    n/a
    		 2.39

    Debt / Equity

    n/a
    		 0.72

    Debt / EBITDA

    n/a
    		 -0.68

    Debt / FCF

    n/a
    		 -0.54

    Interest Coverage

    n/a
    		 -19.07

    Financial Efficiency

    Return on Equity is -111.02% and Return on Invested Capital is -64.82%.

    Return on Equity

    n/a
    		 -111.02%

    Return on Assets

    n/a
    		 -49.79%

    Return on Invested Capital

    n/a
    		 -64.82%

    Revenue Per Employee

    n/a
    		 $208,774.19

    Profits Per Employee

    n/a
    		 $-700,903.23

    Employee Count

    n/a
    		 62

    Asset Turnover

    n/a
    		 0.15

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -105K

    Effective Tax Rate

    n/a
    		 0.24%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 4.11, so Sigilon Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 4.11

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 16.97

    200-Day Moving Average

    n/a
    		 10.29

    Relative Strength Index (RSI)

    n/a
    		 71.26

    Average Volume (20 Days)

    n/a
    		 120,683

    Income Statement

    In the last 12 months, Sigilon Therapeutics had revenue of 12.94M and earned -43.46M in profits. Earnings per share was -1.34.

    Revenue

    n/a
    		 12.94M

    Gross Profit

    n/a
    		 12.94M

    Operating Income

    n/a
    		 -43.67M

    Net Income

    n/a
    		 -43.46M

    EBITDA

    n/a
    		 -41.27M

    EBIT

    n/a
    		 -41.27M

    Earnings Per Share (EPS)

    n/a
    		 -1.34
    Full Income Statement

    Balance Sheet

    The company has 42.07M in cash and 28.06M in debt, giving a net cash position of 14.01M.

    Cash & Cash Equivalents

    n/a
    		 42.07M

    Total Debt

    n/a
    		 28.06M

    Net Cash

    n/a
    		 14.01M

    Retained Earnings

    n/a
    		 -256.8M

    Total Assets

    n/a
    		 55.56M

    Working Capital

    n/a
    		 19.62M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -51.47M and capital expenditures -537K, giving a free cash flow of -52.01M.

    Operating Cash Flow

    n/a
    		 -51.47M

    Capital Expenditures

    n/a
    		 -537K

    Free Cash Flow

    n/a
    		 -52.01M

    FCF Per Share

    n/a
    		 -1.6
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -337.35% and -335.72%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -337.35%

    Pretax Margin

    n/a
    		 -336.53%

    Profit Margin

    n/a
    		 -335.72%

    EBITDA Margin

    n/a
    		 -318.84%

    EBIT Margin

    n/a
    		 -337.35%

    FCF Margin

    n/a
    		 -401.82%

    Dividends & Yields

    SGTX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 -29.47%

    FCF Yield

    n/a
    		 -35.27%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for SGTX.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 23, 2023. It was a backward split with a ratio of 1:13.

    Last Split Date

    n/a
    		 May 23, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:13

    Scores

    Altman Z-Score

    n/a
    		 -6.71

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist